CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) and the European Organisation for
Research and Treatment of Cancer (EORTC) announced today a collaboration
in which Foundation Medicine's comprehensive genomic profiling (CGP)
tests will be used to inform patient eligibility for oncology clinical
trials through the EORTC's Screening Patients for Efficient Clinical
Trial Access (SPECTA) program. SPECTA is a pan-European network built by
the EORTC with key institutions collaborating to provide efficient
access for patients to molecularly driven clinical trials.
"Oncology clinical trials are essential to advancing research and drug
development while enabling patient access to potential clinical
treatment options. Yet, currently only a small fraction of cancer
patients enroll in clinical trials," said Vincent Miller, M.D., chief
medical officer at Foundation Medicine. "The EORTC is a renowned leader
in integrated translational research, and their SPECTA program is an
exciting opportunity for oncologists to utilize our robust genomic
profiling tests to more efficiently match patients with appropriate
clinical trials. Together, Foundation Medicine and the EORTC can work
toward improved access to innovative clinical trials, helping to
accelerate precision oncology for more patients."
The collaboration brings together the EORTC, an independent, non-profit
clinical research organization in cancer, and Foundation Medicine, a
leader in molecular information that offers a suite of CGP assays that
identifies the molecular alterations in an individual's cancer to inform
precision medicine treatment approaches.
"SPECTA serves as a shared and integrated translational and clinical
research infrastructure for knowledge development and ultimately allows
matching patients to clinical trials based on both their clinical
characteristics and the molecular profiles of their tumors," said Denis
Lacombe, M.D., EORTC Director General. "Our collaboration with
Foundation Medicine will provide access to innovative, biomarker-driven
clinical trials that will ultimately usher in a new era of targeted
therapy in oncology."
Under the agreement, Foundation Medicine will provide genomic testing
services for the SPECTA program through three of its genomic profiling
assays: FoundationOne®, its flagship assay for solid tumor
cancers that includes analysis of genomic biomarkers such as
microsatellite instability (MSI) and tumor mutational burden (TMB),
FoundationOne®Heme, an assay for hematologic malignancies and
sarcomas that also includes MSI analysis, and FoundationACT®,
a liquid biopsy assay for solid tumors. Genomic profiling results will
help inform patient eligibility and facilitate enrollment in clinical
trials. Samples will be processed at any one of Foundation Medicine's
laboratories located in the United States and Europe.
The European Organisation for Research and
Treatment of Cancer (EORTC) brings together European cancer clinical
research experts from all disciplines for trans-national
collaboration. Both multinational and multidisciplinary, the EORTC
Network comprises more than 4000 collaborators from all disciplines
involved in cancer treatment and research in more than 800 hospitals and
institutions in over 35 countries.
Through translational and clinical research, the EORTC offers an
integrated approach to drug development, drug evaluation programmes and
medical practices. EORTC Headquarters, a unique pan-European clinical
research infrastructure, is based in Brussels, Belgium, from where its
various activities are coordinated and run.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding of
the genomic changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling assays to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies, immunotherapies and clinical trials.
Foundation Medicine's molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians,
academic researchers and drug developers to help advance the science of
molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine®, FoundationOne®,
FoundationOne®Heme and FoundationACT®
are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
press release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding the value and performance
capabilities of Foundation Medicine's comprehensive genomic profiling
(CGP) assays; the ability of Foundation Medicine's CGP assays to
identify patients eligible to participate in specific clinical trials,
help improve efficiencies, and streamline clinical trial enrollment; and
the ability of a clinical trial to accelerate precision oncology, expand
access to therapies, or improve cancer care. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include the risk that Foundation Medicine's CGP assays and
services will not be able to identify genomic alterations in the same
manner as prior clinical data or prior experience; clinical trial
enrollment does not become more efficient or increase in the expected
manner; and the risks described under the caption "Risk Factors" in
Foundation Medicine's Annual Report on Form 10-K for the year ended
December 31, 2016, which is on file with the Securities and Exchange
Commission, as well as other risks detailed in Foundation Medicine's
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
Foundation Medicine undertakes no duty to update this information unless
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180130005042/en/
Foundation Medicine, Inc.
Kimberly Brown, 617-418-2215
Kaur, +32 2774 1513
Source: Foundation Medicine, Inc.
News Provided by Acquire Media